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Biosimilar agents are approximate copies of branded biologic therapies. Since the ﬁrst
biosimilar was authorized in the European Union in 2006, ﬁfteen additional agents have
been approved by the European Medicines Agency, including two biosimilar monoclonal
antibodies (mAbs). Biosimilar mAbs represent a distinct class given their large molecular
size, complex protein structure, and post-translational modiﬁcations. While guidelines
have been established for the development, approval, and use of biosimilars, further
scrutiny and discussion is necessary to fully understand their potential impact on
clinical outcomes. This review takes a critical look at the structural complexity of
biosimilar mABs, the feasibility of indication extrapolation, the impact of product
variability on immunogenicity, the importance of comprehensive pharmacovigilance, and
the potential for ongoing pharmacoeconomic impact.
© 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Biological medicinal products, or biologics, are a class
of recombinant, protein-based therapeutics, produced
by living organisms (e.g., plants, animals, yeast, and
bacteria) [1]. Over the past two decades, biologics have
revolutionized patient management in multiple disease
states, including solid tumors, hematologic malignan-
cies, autoimmune diseases, and hormone deﬁciencies.
As many of these “blockbuster” drugs reach the end of
their exclusivity rights, the door to the development of
copy versions opens. However, unlike the generics of
small-molecule drugs, exact replicas cannot be made
of biologics because of their structural complexity
and complicated manufacturing process [2,3]. The term
biosimilars was coined to describe any copy of an autho-
rized branded biologic originator that has demonstrated
similarity in a rigorous comparability exercise [3].
Until recently, the only approved biosimilars were
copies of lower molecular weight biologics, such as
growth hormones and hematopoietic growth factors.
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However, in 2013 the European Medicines Agency (EMA)
approved the ﬁrst biosimilars of a monoclonal anti-
body (mAb), inﬂiximab [4,5]. Biosimilars of other mAbs,
including rituximab and trastuzumab, are in develop-
ment, with approval of some expected as early as
2014. The intrinsic complexity of antibody structure, the
heterogeneity introduced by subtle changes in product
manufacturing, and the potential complications associ-
ated with the introduction of biosimilar mAbs to the
marketplace must be brought to the forefront of critical
discussion. While there appears to be great potential
in how biosimilar mAbs may impact the treatment
landscape and beneﬁt patients, there remain a number
of concerns and obstacles that must be addressed.
2. The complexity of monoclonal antibodies
The ﬁrst regulatory guidelines for biosimilars were
published by the EMA in 2005 [6]. Compared with small-
molecule generics and new biologic agents, biosimilars
are evaluated via an abbreviated approval pathway
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Table 1 – Summary of approval process for small-molecule generics, new biologic agents, and biosimilars [2]
Small-molecule generic New biologic agent
(full dossier)
Biosimilar
(reduced dossier)
Quality • Individual quality assessment • Individual quality assessment • Individual quality assessment
• Comparison with reference
product
• Comprehensive comparison with reference product
Pre-clinical • No data required • Full pre-clinical program • Abbreviated pre-clinical program (tolerance, PK/PD)
Clinical • Bioequivalence study • Phase I • Phase I PK/PD study
• Phase II • Phase III study in a sensitive, representative indication
• Phase III in all indications • Risk-management plan
• Risk-management plan
Table 2 – Biosimilars authorized for use in the EU [7]
Biosimilar brand name Active
substance
Therapeutic area Year of
authorization
Abseamed Epoetin alfa Anemia, cancer, chronic kidney failure 2007
Binocrit Epoetin alfa Anemia, chronic kidney failure 2007
Epoetin Alfa Hexal Epoetin alfa Anemia, cancer, chronic kidney failure 2007
Retacrit Epoetin zeta Anemia, autologous blood transfusion, cancer, chronic kidney failure 2007
Silapo Epoetin zeta Anemia, autologous blood transfusion, cancer, chronic kidney failure 2007
Biograstim Filgrastim Cancer, hematopoietic stem cell transplantation, neutropenia 2008
Filgrastim Hexal Filgrastim Cancer, hematopoietic stem cell transplantation, neutropenia 2009
Filgrastim ratiopharma Filgrastim Cancer, hematopoietic stem cell transplantation, neutropenia 2008
Nivestime Filgrastim Cancer, hematopoietic stem cell transplantation, neutropenia 2010
Ratiograstime Filgrastim Cancer, hematopoietic stem cell transplantation, neutropenia 2008
Tevagrastim Filgrastim Cancer, hematopoietic stem cell transplantation, neutropenia 2008
Zarzio Filgrastim Cancer, hematopoietic stem cell transplantation, neutropenia 2009
Inﬂectra Inﬂiximab Rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis,
psoriasis, psoriatic arthritis
2013
Remsima Inﬂiximab Rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis,
psoriatic arthritis, psoriasis
2013
Omnitrope Somatropin Pituitary dwarﬁsm, Prader–Willi syndrome, Turner syndrome 2006
Valtropina Somatropin Pituitary dwarﬁsm, Turner syndrome 2006
a Withdrawn.
(Table 1) [2]. Approval of biosimilars is contingent on
the results of the comparability exercise, which may
include quality data, pre-clinical and clinical data, and
demonstration of clinical therapeutic equivalence. If
the comparison fails at any stage, the product is
not eligible as a biosimilar. Only copy versions that
successfully complete the comparability exercise can be
called “biosimilar”[2,3].
The ﬁrst biosimilars approved by the EMA Committee
for Medicinal Products for Human Use (CHMP) were
of lower molecular weight biologics, including two bio-
similars of somatropin, ﬁve erythropoietin biosimilars,
and seven biosimilars of ﬁlgrastim [7]. Because the
development of biosimilar mAbs is considered more
complex than that of these smaller biologics, the EMA
issued separate guidelines for biosimilar mAbs in 2012.
While similar to the overarching guidelines, the updated
guidelines require more stringent clinical testing and
immunogenic assessment [2]. To date, 16 biosimilars
have received marketing authorizations from the EMA
(Table 2) [7]. This includes two agents that have since
been withdrawn (Filgrastim ratiopharm® [ﬁlgrastim]
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Fig. 1 – Monoclonal antibodies are structurally more complex than small-molecule agents and lower molecular weight
biologics. [8–10]
and Valtropin® [somatropin]) and the approval of the
ﬁrst two biosimilar mAbs, Inﬂectra™ (inﬂiximab) and
Remsima™ (inﬂiximab) [7].
It is clear that biosimilar mAbs are a therapeutic class
separate from the epoetins, ﬁlgrastims, and somatropins.
Monoclonal antibodies are typically higher molecular
weight proteins (~150kDa) with complex secondary
and tertiary structures subject to post-translational
modiﬁcations (Fig. 1) [8–10]. They often comprise mix-
tures of similar molecules that are closely related, yet
not identical [1]. The development of biosimilar mAbs
is complicated by manufacturing and technological
limitations. While the developer of a biosimilar has
access to the originator as a ﬁnal product, there
is no direct access to the proprietary development
data. The developer of the biosimilar must purify the
originator and pursue a reverse engineering process.
Thus, the production of the biosimilar takes on a unique
manufacturing process, likely different from that of the
originator. This may allow for quality-related risks to
be introduced, including process- and product-related
impurities, micro-heterogeneities, and excipients [3,8].
The ability to compare a biosimilar mAb to an
originator mAb on an analytical level remains limited as
well. Laser-induced ﬂuorescence detection, mass spec-
trometry techniques (e.g., hydrogen deuterium exchange
mass spectrometry and electrospray ionization mass
spectrometry), and nuclear magnetic resonance may be
utilized to compare biosimilars and their originators [11–
13]. However, additional techniques are needed to
reﬁne this process and enable further characterization,
including that of the antigen–antibody interaction,
determination of secondary structure, and differences in
protein structure [8].
In September 2013, the EMA issued ﬁnal approval
for two biosimilar inﬂiximab products, Inﬂectra and
Remsima. These agents are indicated for the treatment
of rheumatoid arthritis, ankylosing spondylitis, Crohn’s
disease, ulcerative colitis, psoriatic arthritis, and psoria-
sis [4,5]. The EMA decision supporting Inﬂectra and Rem-
sima not only validates the established EMA process for
biosimilars, but opens the door to approval of biosimilars
of other products nearing or passed their patent ex-
piry dates, including Avastin® (bevacizumab), Enbrel®
(etanercept), Erbitux® (cetuximab), Herceptin® (trastu-
zumab), Humira® (adalimumab), MabThera®/Rituxan®
(rituximab), and Synagis® (palivizumab) [14]. Develop-
ment of several novel biosimilar mAbs is ongoing,
including multiple rituximab biosimilars (CT-P10 [Cell-
trion], GP2013 [Novartis/Sandoz], BI 695500 [Boehringer
Ingelheim], TL011 [Teva/Lonza], SAIT101 [Samsung Bio-
Logics], PF-05280586 [Pﬁzer], MK-8808 [Merck]), and CT-P6
(Celltrion), a biosimilar of trastuzumab in phase III
development [12,15–17]. However, there are several issues
with the continued development and approval of
biosimilar mAbs, and we cannot expect the experience
with biosimilar mAbs to be fully aligned with the
collective experience with lower molecular weight
biosimilar agents.
Scan for more information on how biosimilar
antibodies differ from other biosimilars.
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3. Extrapolation of indications
Because biosimilars are approved through an abbreviated
clinical trial program and may not be tested in all
indications of the originator, extrapolation of indications
is an issue of great concern. The 2012 EMA guidelines on
similar biological medicinal products containing mAbs
indicate that efﬁcacy and safety data in support of a
biosimilar mAb in one disease state may be extrapolated
to other indications of the reference mAb − even if
that indication was not speciﬁcally studied during the
clinical development of the biosimilar − if the evidence
of the comparability exercise is compelling and there
is adequate justiﬁcation. The guidelines suggest that
if different mechanisms of action are considered or
suspected to be relevant, “applicants should provide
relevant data to support extrapolation to all claimed
clinical indications”, including discussion of available
literature related to the involved antigen receptors and
mechanisms of action, potency assays, in vitro assays
that describe the functionality of the molecule, and any
relevant clinical data [2].
Supporters of extrapolation suggest that extrapolation
of scientiﬁc evidence should be seen as a logical
consequence of the comparability exercise principle,
which is founded in physiochemical and biological char-
acterization. Any uncertainties, such as slight differences
of unknown relevance to clinical performance, should
be addressed via comparative clinical data. Furthermore,
Schneider et al. state that the totality of evidence for each
biosimilar applicant should be reviewed as a whole on a
case-by-case basis, with extrapolation viewed not as a
“bonus” for the developer of the biosimilar, but rather
as the applicant’s burden to collect and demonstrate
stringent scientiﬁc evidence [18].
The EMA approval of Inﬂectra is an example of extra-
polation of indications. The Inﬂectra phase I program
focused on patients with active ankylosing spondylitis,
and the phase III program enrolled patients with
active rheumatoid arthritis with inadequate response
to methotrexate [19,20]. However, the EMA approved
Inﬂectra for six indications, namely rheumatoid arthri-
tis, ankylosing spondylitis, Crohn’s disease, ulcerative
colitis, psoriatic arthritis, and psoriasis [4]. While this
experience may not prove typical, and is certainly not
expected to be repeated without justiﬁcation with other
biosimilar products, the issue of extrapolation requires
further consideration.
Those more cautious of extrapolation voice concern
about oversimpliﬁcation. Given that mAbs have com-
plex mechanisms of action that in many cases are
poorly or only partially understood, and that dosing,
administration, clinical study endpoints, and clinical
study populations often vary between indications,
extrapolation will likely not be straightforward [21–24].
While simple cytokines typically have a single ac-
tive site that binds the same receptor or family of
receptors in each indication, mAbs typically perform
diverse functional activities, with multiple aspects
of the same molecule interacting with diverse re-
ceptors [21,25,26]. The net contribution of each mode
of action in vivo, including antibody-dependent cell-
mediated cytotoxicity (ADCC), complement-dependent
cytotoxicity (CDC), and apoptosis, is unknown. Fur-
thermore, dosing can vary widely between indications.
For example, MabThera is indicated for follicular non-
Hodgkin lymphoma (NHL), diffuse large B cell lymphoma,
chronic lymphocytic leukemia, and rheumatoid arthritis,
with dosing ranging from 375mg/m2 administered
weekly to 1000mg administered as two doses 14 days
apart. Duration of treatment may range from 2 weeks to
2 years, depending on the indication [22].
Efﬁcacy endpoints utilized in the clinical devel-
opment of an agent may also vary across clinical
studies. For MabThera, phase III trials have included
response rate [27], progression-free survival [28], event-
free survival [29], and overall survival [30] as primary
endpoints. The EMA guidelines suggest that in some
cases, overall response rate may be a sufﬁciently
sensitive endpoint for mAbs; however, this may not
correlate with survival [2,31]. In addition, the EMA
suggests that survival data should be interpreted with
caution given confounding patient and disease factors.
Unfortunately, reliable surrogate markers of efﬁcacy have
not been established for mAbs, necessitating reliance on
clinical markers.
A ﬁnal challenge for extrapolation may be the variation
in patient characteristics across the populations served
by each indication. For example, patients receiving
Herceptin may have a diagnosis of HER2-positive
metastatic breast cancer, HER2-positive early breast
cancer, or metastatic gastric cancer [32]. Focusing on
breast cancer, patient populations with early disease and
metastatic disease are known to differ by disease burden,
chemotherapy regimens, concomitant medications, and
immune response. While immunogenicity, efﬁcacy, and
safety data may be extrapolated from the early breast
cancer population to the metastatic population, the
reverse, extrapolation from the metastatic population to
the early disease population, may represent a risk for pa-
tients. Despite these issues, a phase III study designed to
demonstrate equivalence in efﬁcacy and safety of CT-P6,
a trastuzumab biosimilar, is ongoing in 475 patients with
HER2-positive metastatic breast cancer [17].
In 2013, the European Crohn’s and Colitis Organisation
released a position statement on the use of biosimilars in
the treatment of inﬂammatory bowel disease (IBD). The
organization stated that “a biosimilar proven effective
and safe for one indication may not necessarily be
effective and safe for a second indication for which
the reference biologic has been shown to be safe and
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effective”. Furthermore, the group urged that studies in
patients with IBD be required to establish efﬁcacy and
safety for this indication given that experience with
current biologics has shown that efﬁcacy in IBD does not
necessarily correlate to efﬁcacy in other indications,
such as rheumatoid arthritis. The European Crohn’s and
Colitis Organisation’s statement represents the ﬁrst time
a group of physicians has taken an open stance against
extrapolation of indications for biosimilars [33]. The
Association of the British Pharmaceutical Industry (ABPI)
has also provided a position statement against automatic
indication extrapolation for biosimilar products, noting
that each biosimilar should demonstrate safety and
efﬁcacy through robust phase III trials, mirroring the
requirements placed on originator agents [34].
4. Product variability and the potential for
immunogenicity
The current framework for development of biosimilar
mAbs aims to use advanced technology to demonstrate
that there are no relevant differences between the bio-
similar and the originator. Slight differences in structure
of the active substance, post-translational modiﬁcations,
and impurity proﬁle may be considered acceptable by
the EMA, given adequate justiﬁcation and non-clinical
and clinical data [2]. This may be based on the principle
that it is common for originator biologics to undergo
manufacturing process improvements over time that
trigger subsequent comparability exercises [35]. These
manufacturing changes may lead to micro-variants
within the drug proﬁle, which may have no clinical effect
or may completely shift the immunogenicity proﬁle,
with changes in immune reaction potentially leading
to altered efﬁcacy and safety [2,36,37]. The presence
and acceptance of these variations speak to the level
of tolerance of non-clinically signiﬁcant micro-variants
within the regulatory authorities. However, the issue of
immunogenicity may pose an even greater challenge
as biosimilar mAbs, and thus additional variability,
are introduced into the treatment landscape. The EMA
acknowledges that “the immunogenicity of mAbs is
complex and there are a number of often poorly
understood factors which make it difﬁcult to predict
with any certainty whether a therapeutic or diagnostic
monoclonal antibody is likely to provide a clinically
relevant immune response.” [38]
Glycosylation is one way in which antibodies introduce
variation.This may include differential addition of sugars
and alternative branching of sugar chains. The presence
or absence of even one sugar residue can affect the
biologic activity of the agent [37,39,40]. For proteins pro-
duced in bacteria, such as insulin, this is not a concern, as
bacteria do not typically induce glycosylation. However,
for proteins produced via more complex eukaryotic
organisms, the presence of glycosyltransferases and
glycosidases induces modiﬁcations. For example, altered
glycosylation patterns may change the shielding of the
protein backbone, affecting the immunogenic properties
of the molecule [1,38]. At this time, characterization of
these variations is limited by available technology and
procedures. This is further complicated by the fact
that glycosylation is neither standardized nor template-
driven, but rather relies on the interrelated activity
of the endoplasmic reticulum, Golgi apparatus-based
enzymes, and downstream processing. Therefore, while
an originator biologic and a biosimilar possess the same
polypeptide sequence, theymay differ in the composition
of their attached sugar chains. Such similar, but not
exact, replicas are known as glycoforms [1,40].
In a study comparing biosimilar erythropoietins
from around the world using high-resolution gel
electrophoresis, the composition of the agents was
found to vary and the balance of glycoforms was not
uniform [41]. While some advances have been made,
including the manipulation of host cells to produce
favored glycoforms, complete control of glycosylation
has yet to be established [42]. Not only does the presence
of non-standardized glycoforms pose a risk, but the
technology to routinely determine composition equiv-
alence between a biologic originator and subsequent
biosimilars is not yet available. These subtle differences
in glycosylation may impact the patient experience
as changes in glycosylation may ultimately inﬂuence
binding, immunogenicity, and effector activity [8].
Small production ﬂuctuations, such as those related
to cell culture pH, temperature, and media ingredients,
also may impact the ﬁnal product, introducing micro-
heterogeneities such as alternative disulﬁde pairings/
disulﬁde shufﬂing, deamidation, (methionine) oxidation,
crystallization of N-terminal glutamine residues, and
partial enzymatic cleavage [8,43–45]. Subtle changes
in the molecular shape of the protein may trigger
insolubility of the protein, loss of biological function,
or increased immunogenicity due to the uncovering of
antigenic portions of the molecule that would normally
be hidden from the immune system [1,46–48]. Indeed,
the immunogenicity of biologics, including biosimilars,
should be viewed as unpredictable and unforeseeable.
The development of anti-drug immune reactions has
been well established with the use of biologics [47,48].
A well-known example of these reactions is the increase
in antibody-mediated pure red cell aplasia (PRCA)
associated with a single formulation of Eprex® (epoetin
alpha) used in patients requiring chronic dialysis. It is
hypothesized that a minor manufacturing change, likely
a switch from human serum albumin to polysorbate 80 in
an effort to avoid potential contamination from viruses
and prions, induced an immune reaction in which the
patient’s antibodies neutralized not only the drug, but
also the body’s natural epoetin [49]. While mAbs do not
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typically induce antibodies that cross-react and neutral-
ize an endogenous counterpart, such as what occurred
with Eprex, this example does speak to the potential
signiﬁcant impact of small manufacturing variations
between products and within individual products.
Additionally, consideration should be taken when
different host cells are used for production of the
biosimilar and the originator. For example, a biosimilar
may be perceived to have a low risk of immunogenicity
given the mechanism of action established for its
originator counterpart. However, if it is produced using
a novel expression system, this risk may be changed due
to the introduction of impurities [38].
While the potential for development of immuno-
genicity is clear, the assessment of immune response
may not always be straightforward. Adult patients with
psoriatic arthritis who are managed with inﬂiximab
monotherapy (5mg/kg) are 5 times more likely to develop
anti-drug antibodies (ADAs) than patients receiving com-
bination therapy with inﬂiximab (5mg/kg) and metho-
trexate. This is likely due to the immunosuppressive
qualities of methotrexate. Furthermore, compared to
patients with psoriatic arthritis treated with higher-dose
inﬂiximab (5mg/kg), adult patients with rheumatoid
arthritis who are treated with lower-dose inﬂiximab
(3mg/kg) have a two-fold higher risk of developing ADAs.
When immune response is compared between adult
patients with rheumatoid arthritis and adolescent
patients with juvenile idiopathic arthritis, there is a
ﬁve-fold increase in unwanted immune response in
younger patients, even though both groups are treated
with the same dose (3mg/kg). When the adolescent
dose was raised to 6mg/kg, the immune reaction in this
population was reduced by approximately a factor of
four. While cross-trial comparison of data is inherently
ﬂawed, these data do highlight potential differences in
immune response based on dosing, regimen, indication,
and patient population [50,51].
Assessment of immunogenicity in non-clinical animal
models is not reliably predictive of unwanted immune
response in humans. The CHMP guidelines therefore
do not require non-clinical studies aimed at predicting
immunogenicity in humans [2]. However, the currently
required duration of comparative studies between
biosimilars and their originators may not be long
enough to detect potential immunogenicity effects. For
example, EMA guidelines on somatropin biosimilars
require only one randomized controlled trial of at least
6 months duration prior to marketing authorization [52].
Unfortunately, there has been a push for limiting non-
clinical and clinical development programs for bio-
similars based on the clinical proﬁle and post-marketing
safety data available for the originator product [8].
However, given the propensity for variation between
products and the increased risk for immunogenicity, it
is likely that these limited development programs will
be insufﬁcient to demonstrate appropriate efﬁcacy and
safety of biosimilars. It is recommended that a robust
and systematic clinical program be developed to assess,
characterize, and mitigate potential risks and that post-
marketing surveillance be employed to further ensure
patient safety.
5. Challenges in pharmacovigilance
A risk management plan, including immunogenicity
assessment, should be in place for all biologics, including
biosimilars. The goals of the plan should be to
collect additional information as early as possible to
further characterize the risk proﬁle and to inform the
safe and effective use of the product [53]. The EMA
recommends that a comprehensive pharmacovigilance
plan be submitted as part of the original approval
application, taking into account immunogenicity risks
identiﬁed during product development as well as any
anticipated future risks. The risk management plan
should take a multidisciplinary approach and include
pre-authorization and post-authorization testing. Addi-
tional post-marketing safety commitments may include
targeted questionnaires, phase IV studies, registries,
and specialized follow-up for long-term use [54,55].
Evaluation of immunogenicity should include immune-
response case deﬁnitions, infrastructure for further
processing patient samples, and support for physicians
reporting adverse drug reactions [2,53,55].
Starting in the fourth quarter of 2013, an inverted
black triangle () and a statement summarizing the
additional monitoring requirements and responsibility
of healthcare professionals to report any suspected
adverse reactions must be placed on the summary of
product characteristics (SPC) for all medical products
subject to additional monitoring, including new biologics
and biosimilars. All materials distributed to patients
and healthcare professionals that include information
on an agent subject to additional monitoring are
required to include information about the monitoring
requirements. A list of medicines with additional
monitoring requirements will be published by the EMA
and reviewed monthly by the Pharmacovigilance Risk
Assessment Committee (PRAC). Of note, this legislation
affects only those agents authorized in the European
Union (EU) after 1 January 2011. Agents will typically be
assigned the inverted black triangle for an initial duration
of ﬁve years, with the option for regulators to extend this
time period [53,56].
In order to support the pharmacovigilance plan,
it is important that each agent administered to a
patient be clearly identiﬁed and traceable. As mandated
by the World Health Organization (WHO), biosimilars
are allocated the same international non-proprietary
name (INN), also referred to as a generic name, as their
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originator biologic. In some instances in which signif-
icant differences in glycosylation have been identiﬁed,
such as with the epoetins, an additional Greek letter
may be assigned (e.g., epoetin alfa and epoetin zeta).
Based on the use of identical INNs and the potential
differences between biosimilars and their originators, the
Medicines and Healthcare Products Regulatory Agency
(MHRA) and the ABPI recommend that a product’s brand
name be used when prescribing a biologic or biosimilar
and when reporting adverse drug reactions associated
with a biologic or biosimilar [34,57,58]. In anticipation
of biosimilars of the mAb rituximab, Section 4.4 of the
MabThera (rituximab) SPC was revised to read “in order to
improve the traceability of biological medicinal products,
the trade name of the administered product should be
clearly recorded (or stated) in the patient ﬁle.” [22]
Given that biosimilars are similar to but not identical to
their originators, there is no scientiﬁc basis to substitute
a biosimilar for a branded product, and automatic substi-
tution could potentially put patients at risk by preventing
adequate traceability or encouraging switching between
products. While there is currently no EU-wide guidance
on automatic substitution with biosimilars, this action is
not allowed in most countries (Table 3) [59–63].
6. Pharmacoeconomic impact of biosimilar
antibodies
Biopharmaceuticals are a fast-growing segment of
the worldwide pharmaceutical market, with growth
estimated at over 20% per year, bolstered by a robust
development pipeline, approval of newer agents for
more common disease states, increased utilization,
and expanding indications [64,65]. The European Generic
Medicines Agency has estimated that, as of 2010,
the top ten bestselling biosimilars had generated a
savings of €1.4 billion for the European healthcare
system [66]. Global Industry Analysts, Inc. forecasts
that the global market for biosimilars will reach
US$ 18 billion by 2017 [34].
While it requires an estimated US$ 1−2 million and
up to three years to bring a standard generic to market,
it is estimated that it requires US$ 10−40 million and
takes six to nine years to bring a biosimilar to market.
The set-up investment for a novel manufacturing process
is estimated at US$ 250–450 million [65,67]. Furthermore,
while generics are typically marketed at as low as 20% of
the brand cost in the United Kingdom (UK), biosimilars
are marketed at as high as 70−85% of the brand cost, a
signiﬁcant decline in savings for the consumer [65,68].
Uptake of biosimilars has varied across Europe from
close to 0% (Belgium) to approximately 70% (Romania
and Greece). While there has been signiﬁcant uptake
of ﬁlgrastim biosimilars in several countries, reaching
80% in the UK, uptake of biosimilar somatropin remains
consistently low (<20%) across the EU. Future growth
is anticipated with around US$ 25 billion in sales
forecasted by 2020, expected to be driven largely by the
United States market expansion [69].
7. Summary
The ﬁrst biosimilars, somatropins and erythropoietins,
were introduced in the EU in the mid-2000s. The most
recent agents approved in this space are biosimilars
of mAbs. The development of biosimilar mAbs is
complicated by their complex molecular structure,
potential for post-translational modiﬁcations, and mul-
tidimensional manufacturing process. In an effort to
ensure patient safety and to address issues of micro-
heterogeneities between biosimilars, including the po-
tential for immunogenicity, robust clinical development
programs must be required for each new agent. Each
marketing application should include studies supporting
the use of the agent in target disease states and
patient populations, as well as a robust post-marketing
pharmacovigilance plan. Biosimilars have the potential
to beneﬁt patients and change the overall treatment
landscape; however, they also require great responsibility
from the wider healthcare community to ensure their
appropriate development and use.
Scan for more information and expert commen-
tary on the incorporation of biosimilar antibodies
into oncology and hematology.
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Table 3 – EU countries with speciﬁc measures limiting or prohibiting substitution of biosimilars [59]
Country Year Summary
France 2006 Automatic substitution of biosimilars is prohibited
Germany 2008 Automatic substitution of biosimilars is prohibited
2011 A pharmacist may substitute a product for an identical product, even if the brand name is different. The
German Pharmacists Association states that in the case of biological products, only those biologics that
contain the same raw material and undergo the same manufacturing process are “bio-identical” and qualify
for substitution. [60]
Greece 1976 Pharmacists are obliged to provide the exact pharmaceutical product mentioned in a medical prescription,
and prohibited from switching to another pharmaceutical product
1993 Pharmacists may not substitute the pharmaceutical product stated in a prescription with any other product
2013 The Greek National Organization for Medicines recommends against automatic
substitutions/interchangeability of reference biologicals and their biosimilars [61]
Italy 2007 Based on guidance from the Ministry of Health, the Italian Council of State issues an opinion stating that
biosimilars cannot be substituted
Slovenia 2008 Slovenian Medical Society guidelines prohibit the substitution of biologics
Spain 2007 The Spanish Health Agency states that biologics are not substitutable
Sweden 2007 The Swedish Medicines Agency issues a statement indicating that biologics are not interchangeable and are
not recommended for substitution
2011 Biosimilars are included on a list of drugs not suitable for extended substitution on the basis that they are
not medically comparable and might elicit different immunologic responses
UK 2010 Automatic substitution of biologics is prohibited. The Department of Health (DoH) and the Association of the
British Pharmaceutical Industry (ABPI) propose to the Medicines and Healthcare Products Regulatory
Agency (MHRA) that biologics/biosimilars be exempt from automatic substitution and that biologics only be
substituted with the prescribing physician’s knowledge and prior consent. The MHRA states that it is best
practice to prescribe by brand name to ensure traceability.
Czech Republic 2008 Automatic substitution of any originator product with a generic must be prohibited by the physician
2009 The Czech Society for Oncology issues a statement noting that biosimilars are not interchangeable with
their originators [62]
Denmark 2010 Biosimilars can be substituted for each other, but not for originator products on the substitution lists issued
by the Danish Medicines Agency
Finland 2009 The Finnish Regulatory Agency states that products given parenterally are not substitutable
Hungary 2009 Biosimilar products are not on the positive substitution list provided by the Hungarian National Institute
of Pharmacy
Norway 2010 Biosimilar products are not on the positive substitution list provided by the Norwegian Medicines Agency
Slovakia 2008 Biosimilar products are not on the positive substitution list provided by the Slovak Ministry of Health
Austria 2005 Physicians are obliged to prescribe by brand name and to look for the cheapest but best medicines for their
patients. Therefore, there is no obligation to substitute biologics, and the responsibility lies with the physician.
2012 The Austrian Regulatory Authority recommends against pharmacists automatically substituting an originator
product with a biosimilar [63]
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